Trajan Wealth LLC Has $18.25 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Trajan Wealth LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,023 shares of the medical research company’s stock after selling 757 shares during the period. IQVIA makes up about 1.1% of Trajan Wealth LLC’s holdings, making the stock its 25th biggest position. Trajan Wealth LLC’s holdings in IQVIA were worth $18,252,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IQV. Wealth Enhancement Advisory Services LLC increased its position in IQVIA by 5.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,898 shares of the medical research company’s stock worth $1,492,000 after purchasing an additional 300 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in IQVIA by 3.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 170,451 shares of the medical research company’s stock worth $43,105,000 after purchasing an additional 5,240 shares during the last quarter. Norden Group LLC acquired a new position in IQVIA in the 1st quarter worth about $703,000. Financial Sense Advisors Inc. acquired a new position in IQVIA in the 1st quarter worth about $5,351,000. Finally, First Trust Direct Indexing L.P. increased its position in IQVIA by 2.7% in the 1st quarter. First Trust Direct Indexing L.P. now owns 9,299 shares of the medical research company’s stock worth $2,352,000 after purchasing an additional 243 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on IQV shares. UBS Group upped their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Evercore ISI decreased their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Barclays dropped their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Finally, Royal Bank of Canada began coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.27.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of IQVIA stock opened at $216.34 on Wednesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The firm’s 50-day simple moving average is $236.50 and its 200-day simple moving average is $230.16. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The firm has a market cap of $39.44 billion, a P/E ratio of 28.10, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.